Armata Pharmaceuticals, Inc. (ARMP) Investor Relations Documents

Armata Pharmaceuticals, Inc. (ARMP) investor relations documents from the company's IR site: 2 presentations, 10 press releases; latest deck 2026-05-15. Read in-app with summaries. First-party data.

Download Corporate Presentation: Armata Pharmaceuticals (NYSE American: ARMP) is a biotechnology company developing pathogen-specific phage therapeutics to address antibiotic-resistant infections.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-20Press releaseArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned
2026-07-13Press releaseArmata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Comp
2026-06-23Press releaseArmata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defens
2026-05-15PresentationDownload Corporate Presentation
2026-05-04Press releaseArmata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
2026-04-27Press releaseArmata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Bo
2026-02-23Press releaseArmata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
2026-01-13Press releaseArmata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority S
2025-11-18Press releaseArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research
2025-11-10Press releaseArmata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angel
2025-10-22Press releaseArmata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage
2025-10-22PresentationDownload IDWeek™ 2025 Presentation
2025-04-28Proxy statementhttps://investor.armatapharma.com/download/Armata+Pharmaceuticals+Inc+2025+Annual+Meeting+Proxy.pdf
2022-10-17Proxy statementhttps://investor.armatapharma.com/download/Armata+Pharmaceuticals+Inc+2022+Annual+Meeting+Proxy.pdf

ARMP overview · ARMP earnings · ARMP financials · ARMP KPIs · ARMP ownership · ARMP peers · ARMP filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.